Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research

Collaboration Overview - Lunit has announced a collaboration with Daiichi Sankyo to enhance biomarker discovery and optimize translational research using Lunit SCOPE digital pathology products across two oncology programs [1][2][3] Technology and Applications - Daiichi Sankyo will utilize Lunit SCOPE solutions, including SCOPE uIHC for quantitative IHC analysis and SCOPE IO for immune phenotyping and spatial analysis, to identify novel biomarkers and improve clinical trial support [2][3] - Lunit SCOPE aims to extract insights from pathology slides, quantifying tumor microenvironments and predicting molecular profiles to inform trial design [3] Research and Development Impact - The collaboration will involve exploratory research projects across multiple cancer types, potentially influencing future trial designs, biomarker strategies, and clinical development plans [3] Company Background - Lunit, founded in 2013, is a leader in AI for cancer diagnostics, offering solutions that enhance early detection and treatment decisions across the cancer care continuum [4][5] - The company’s Lunit SCOPE platform is utilized in research partnerships for biomarker research and companion diagnostic development [5][6] Global Reach - Lunit's solutions are trusted by over 10,000 sites in more than 65 countries, combining medical expertise with evolving datasets to impact patients, clinicians, and researchers [6]